Cancer immunotherapy: breaking the barriers to harvest the crop.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 15340404.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Successful translation of modern molecular immunology into effective cancer immunotherapy is threatened by regulatory barriers and challenges to the development of novel agents and combinatorial strategies through effective public-private partnerships. For its promise to be fully realized, both the National Cancer Institute and Food and Drug Administration must take active steps to help academic investigators and companies jointly navigate the pathways from laboratory to clinic.
Medical subject headings
- Allergy and Immunology
- Immunotherapy
- Neoplasms